View ValuationSartorius 将来の成長Future 基準チェック /46Sartorius利益と収益がそれぞれ年間20.7%と8.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17.4% 16.2%なると予測されています。主要情報20.7%収益成長率16.16%EPS成長率Life Sciences 収益成長20.2%収益成長率8.8%将来の株主資本利益率17.41%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.すべての更新を表示Recent updatesお知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.Reported Earnings • Jul 22First quarter 2022 earnings releasedFirst quarter 2022 results: EPS: €3.01. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 128% from 1Q 2021). Profit margin: 20% (up from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.9% growth forecast for the industry in Germany.Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is 5.1% above last closing price of €385. Stock is down 21% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 15% above last closing price of €363. Stock is down 26% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.Buying Opportunity • May 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.Reported Earnings • Apr 27First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €3.00. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 151% from 1Q 2021). Profit margin: 20% (up from 10% in 1Q 2021). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is forecast to grow 15%, compared to a 11% growth forecast for the industry in Germany.Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €304, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 140% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €290 per share.Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €416, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 326% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 20% below last closing price of €480. Stock is up 78% over the past year.Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).Price Target Changed • Feb 23Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €432. As of last close, the stock is up 108% over the past year.Reported Earnings • Feb 20Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 30New 90-day high: €370The company is up 14% from its price of €325 on 30 October 2020. The German market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €320. As of last close, the stock is up 87% over the past year.Is New 90 Day High Low • Oct 22New 90-day high: €331The company is up 22% from its price of €271 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €173 per share.Is New 90 Day High Low • Oct 01New 90-day high: €303The company is up 22% from its price of €248 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €187 per share.業績と収益の成長予測XTRA:SRT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,5073857211,1261912/31/20274,1063305841,0152212/31/20263,752258443839223/31/20263,554163443887N/A12/31/20253,538155395837N/A9/30/20253,517134479874N/A6/30/20253,468104575919N/A3/31/20253,444967121,070N/A12/31/20243,38184566976N/A9/30/20243,32478479924N/A6/30/20243,34178350838N/A3/31/20243,312149144697N/A12/31/20233,396206294854N/A9/30/20233,608358215821N/A6/30/20233,850495204807N/A3/31/20234,053566182744N/A12/31/20224,175678212734N/A9/30/20224,035534175690N/A6/30/20223,880489243723N/A3/31/20223,683434414837N/A12/31/20213,449319466873N/A9/30/20213,183372422770N/A6/30/20212,908332439737N/A3/31/20212,617254350627N/A12/31/20202,336210271512N/A9/30/20202,151181312503N/A6/30/20201,989154227427N/A3/31/20201,901165171385N/A12/31/20191,827157N/A377N/A9/30/20191,768171N/A337N/A6/30/20191,702166N/A318N/A3/31/20191,637153N/A312N/A12/31/20181,566141N/A245N/A9/30/20181,518138N/A245N/A6/30/20181,460126N/A244N/A3/31/20181,426115N/A223N/A12/31/20171,405115N/A207N/A9/30/20171,37691N/A185N/A6/30/20171,37796N/A182N/A3/31/20171,341105N/A173N/A12/31/20161,300103N/A170N/A9/30/20161,25099N/A145N/A6/30/20161,205101N/A112N/A3/31/20161,15996N/A132N/A12/31/20151,11585N/A125N/A9/30/20151,07676N/A160N/A6/30/20151,00361N/A153N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SRTの予測収益成長率 (年間20.7% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: SRTの収益 ( 20.7% ) はGerman市場 ( 17.1% ) よりも速いペースで成長すると予測されています。高成長収益: SRTの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: SRTの収益 ( 8.8% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: SRTの収益 ( 8.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SRTの 自己資本利益率 は、3年後には低くなると予測されています ( 17.4 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:37終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sartorius Aktiengesellschaft 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35 その他のアナリストを表示
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.
お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.
お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025
お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025
お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025
お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.
お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024
お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024
お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024
お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.
お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.
お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023
お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023
Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.
Reported Earnings • Jul 22First quarter 2022 earnings releasedFirst quarter 2022 results: EPS: €3.01. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 128% from 1Q 2021). Profit margin: 20% (up from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.9% growth forecast for the industry in Germany.
Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is 5.1% above last closing price of €385. Stock is down 21% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.
Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 15% above last closing price of €363. Stock is down 26% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.
Buying Opportunity • May 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.
Reported Earnings • Apr 27First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €3.00. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 151% from 1Q 2021). Profit margin: 20% (up from 10% in 1Q 2021). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is forecast to grow 15%, compared to a 11% growth forecast for the industry in Germany.
Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €304, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 140% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €290 per share.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €416, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 326% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.
Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).
Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 20% below last closing price of €480. Stock is up 78% over the past year.
Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.
Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).
Price Target Changed • Feb 23Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €432. As of last close, the stock is up 108% over the past year.
Reported Earnings • Feb 20Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 30New 90-day high: €370The company is up 14% from its price of €325 on 30 October 2020. The German market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.
Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €320. As of last close, the stock is up 87% over the past year.
Is New 90 Day High Low • Oct 22New 90-day high: €331The company is up 22% from its price of €271 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €173 per share.
Is New 90 Day High Low • Oct 01New 90-day high: €303The company is up 22% from its price of €248 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €187 per share.